United Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Lowered by Amalgamated Bank

Amalgamated Bank reduced its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 15.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,565 shares of the biotechnology company's stock after selling 3,841 shares during the quarter. Amalgamated Bank's holdings in United Therapeutics were worth $7,728,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. QRG Capital Management Inc. raised its holdings in United Therapeutics by 6.9% during the third quarter. QRG Capital Management Inc. now owns 16,380 shares of the biotechnology company's stock worth $5,870,000 after purchasing an additional 1,059 shares in the last quarter. National Pension Service raised its stake in shares of United Therapeutics by 38.2% during the 3rd quarter. National Pension Service now owns 113,742 shares of the biotechnology company's stock worth $40,759,000 after buying an additional 31,442 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of United Therapeutics by 3.6% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 196,019 shares of the biotechnology company's stock valued at $70,243,000 after buying an additional 6,839 shares during the period. Emerald Advisers LLC purchased a new stake in shares of United Therapeutics in the third quarter valued at approximately $692,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in United Therapeutics during the third quarter worth $111,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Analysts Set New Price Targets

Several brokerages have commented on UTHR. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research report on Tuesday, August 20th. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Finally, Bank of America dropped their price objective on United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $5.08 during mid-day trading on Thursday, reaching $402.57. 370,193 shares of the stock were exchanged, compared to its average volume of 464,712. The business's fifty day simple moving average is $357.42 and its 200 day simple moving average is $320.37. The stock has a market capitalization of $17.97 billion, a PE ratio of 17.46, a PEG ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $405.98.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the previous year, the business earned $5.38 earnings per share. The business's revenue for the quarter was up 22.9% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Co. will post 25.57 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 14,700 shares of the business's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $374.46, for a total value of $5,504,562.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $964,983.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $344.18, for a total value of $1,239,048.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company's stock, valued at $44,743.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 14,700 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $964,983.42. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,422 shares of company stock worth $29,229,828 in the last 90 days. 11.90% of the stock is owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.